May 1, 2013

Drug maker Actavis has acquired rights to a treatment for an experimental bacterial vaginosis from Valeant Pharmaceuticals International for about $55 million, the drug makers said.

April 11, 2013

Chattem announced the launch of Allegra Anti-Itch Cooling Relief Cream and Allegra Anti-Itch Intensive Relief Cream.

April 10, 2013

Chattem introduced Cortizone 10 Poison Ivy Relief Pads featuring a new anti-itch format trademarked the Snapplicator.

April 4, 2013

Swiss drug maker Covis Pharma will buy U.S. rights to five drugs from Sanofi, Covis said.

March 22, 2013

Disease relapse rates and worsening of disability were low among patients taking a drug made by Genzyme for multiple sclerosis, the company said.

March 4, 2013

The Centers for Disease Control and Prevention set the stage for the first quadrivalent influenza vaccine to be introduced in the 2013-2014 flu season, according to a report in The Wall Street Journal.

February 25, 2013

The generic drug tidal wave became a tsunami in 2012, with some of the world's top-selling pharmaceuticals swamped by generic competition, and health plan payers scrambling to reap billions of dollars in financial savings.

February 19, 2013

Mylan and Biocon have a deal to develop and sell generic insulin-analog products for diabetes, Mylan said.

February 19, 2013

Sergeant's Pet Care Products has launched a generic version of a commonly used spray for killing fleas and ticks in dogs and cats, the company said Tuesday.

February 12, 2013

The Colon Cancer Challenge Foundation, a nonprofit organization dedicated to reducing colorectal cancer incidence and death throughout the United States, presented Sanofi with its annual Blue Star Corporate Award.

February 11, 2013

Sun & Skin Care Research announced that it has completed the acquisition of the Bull Frog sunscreen brand from Chattem, a division of Sanofi U.S.

February 8, 2013

A new report by Francesco International identified $35.7 billion worth of potential Rx-to-OTC switches in a wide range of indications, from hypertension and chronic obstructive pulmonary disorder to high cholesterol and erectile dysfunction, and the Food and Drug Administration has been looking at ways technology and pharmacists could be employed to ensure that patients taking drugs new to the consumer health space take them appropriately.

With growth in traditional pharmaceuticals expected to slow down significantly, a growing number of drug makers — branded and generic alike — see specialty drugs as their main sources of revenue for the foreseeable future. At the same time, those drug makers not invested in specialty may be looking for growth opportunities in consumer health.

February 8, 2013

During a quarterly conference call Thursday, Sanofi president global operations Hanspeter Spek noted that Sanofi's consumer arm Chattem will be relaunching the heartburn remedy Rolaids.

January 29, 2013

Sanofi announced today that Auvi-Q (epinephrine injection, USP) is now available in U.S. retail pharmacies nationwide with a prescription from a healthcare provider.

January 28, 2013

The Food and Drug Administration has accepted a regulatory approval application from Genzyme for an experimental treatment for multiple sclerosis, the company said Monday.

January 10, 2013

The Food and Drug Administration is ordering the makers of several sleep drugs to lower the dosage due to the risk that they can impair patients the morning after, the agency said Thursday.

January 7, 2013

Sanofi announced that its U.S. Consumer Healthcare Division Chattem, completed the acquisition of the worldwide rights to the Rolaids brand from McNeil Consumer Healthcare for an undisclosed amount.

January 4, 2013

According to a Bloomberg report, Abbott Laboratories, Johnson & Johnson and Sanofi are all potential suitors for Bausch & Lomb's eye care business in a deal that could be valued as high as $10 billion.

January 2, 2013

Consumers who purchased Chattem’s ACT Total Care Anticavity Fluoride Mouthwash between Jan. 1, 2009, and June 30, 2010, may be entitled to a cash refund from a class action settlement, according to a statement issued by the manufacturer.

November 29, 2012

Just how much of an impact the loss of patent protection can have on a blockbuster drug became clear earlier this year.


November 29, 2012

In 2011 and 2012, the steady surge of blockbuster pharmaceuticals falling off the patent cliff became a stampede. An astonishing number of big-selling drugs that had established and sustained branded drug makers’ profits for years fell victim to the expiration of their patent lives and market exclusivity, roiling the pharmaceutical marketplace and redefining the pricing model for many of the most widely prescribed classes of medicines.


November 27, 2012

Indian generic drug maker Wockhardt received three new drug approvals from the Food and Drug Administration, agency records show.

October 22, 2012

Sanofi Pasteur announced Monday the presentation of three clinical trials of an experimental influenza vaccine.

October 18, 2012

Sanofi Pasteur on Thursday announced it has filed for approval of a four-strain flu shot to the Food and Drug Administration.